secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001193125-25-143658
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech enters CEO severance agreement providing 12-18 months pay and equity vesting
--------------------------------------------------------------------------------

- Severance pay: 12 months base salary on qualifying termination; 18 months if termination within 6 months pre- or 12 months post-Change in Control.
- Equity awards: 12-month vesting acceleration (standard) or 100% vesting at target (Change in Control scenario).
- Pro-rated bonus for termination year plus unpaid prior-year bonus; subject to release and non-compete compliance.
- CEO Mai-Britt Zocca: addendum to existing service agreement effective June 19, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525143658/0001193125-25-143658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525143658/d90779d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-143658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer